A study published by the Journal of Traditional and Complementary Medicine and e-published by the U.S. National Library of ...

Funded by Prostate Cancer UK, the ICR team focused on genes involved in the PI3K-AKT pathway, which is frequently mutated in ...

Two newly identified disease-causing genes, known as Bzw2 and Eif5a2, have been implicated in early prostate cancer ...

The global burden of anxiety- and depression-related disorders is on the rise. While multiple drugs have been developed to treat these conditions, current medications have several limitations, ...

Kazia Therapeutics Limited (NASDAQ: KZIA ) ("Kazia" or the "Company"), an oncology-focused drug development company, today announced that it has closed its previously announced registered direct ...

Johnson & Johnson, already a big player in neuroscience drugs, is adding to its portfolio and pipeline with a deal to acquire ...

Researchers from Tokyo University of Science uncover cellular and molecular mechanisms underlying the antidepressant-like effects of the delta opioid receptor agonists, paving the way for its clinical ...

Eli Lilly has unveiled a $2.5 billion deal to acquire rights to a cancer therapy being developed by Scorpion Therapeutics in ...

The acquisition will expand Lilly's oncology pipeline with STX-478, the differentiated and potentially best-in-class, mutant-selective PI3Ka inhibitor currently in a Phase 1/2 clinical trialSTX-478 ...

For Lilly, Citi is acting as exclusive financial advisor and Ropes & Gray LLP is acting as legal counsel. For Scorpion, Centerview Partners LLC is acting as lead financial advisor with additional ...

Eli Lilly and Company (NYSE: LLY) and Scorpion Therapeutics, Inc. ("Scorpion"), a private biotechnology company developing small molecule precision oncology therapies, today announced a definitive ...